Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma

Bispecific antibodies (BsAb) have emerged as a leading treatment modality in patients suffering from B-cell non-Hodgkin’s lymphoma (B-NHL). However, treatment failure is common and may potentially be attributed to pre-existing or emerging T-cell exhaustion. CD39 catalyzes—together with CD73—the hydr...

Full description

Bibliographic Details

Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	Carsten Müller-Tidow, Peter Dreger, Joseph Kauer, Wolfgang Huber, Clara Kolbe, Berit Brinkmann, Sascha Dietrich, Tobias Roider
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-01-01
Online Access:	https://jitc.bmj.com/content/13/1/e009245.full